Solve Problems and Meet Lifestyle Needs with Daily Replacement CLs

Daily replacement contact lenses–now available in toric and multifocal designs–are great problem solvers for many new and existing contact lens patients. Listen well to a patient’s vision needs and lifestyle patterns, then show how daily replacement lenses can meet those needs.

We often talk about lifestyle prescribing for patients when it comes to spectacles, but the same philosophy holds true for our contact lens patients. Honing your communication skills in the exam lane can make all the difference. Start by asking the right questions. This is key to creating opportunities for prescribing daily replacement contact lenses. You should not attempt to present solutions to a patient’s problem before he realizes/admits there is a problem. Only after a patient has verbalized there is room for improvement will he be receptive to the solutions you offer. Explain the many benefits of daily replacement contact lenses, then allow your patients to experience the benefits by giving them at least 10 pairs of diagnostic lenses to try.

Daily Replacement CLs Reduce Allergens

Ask your patients about eye allergies and the subsequent disadvantages of decreased wear time during allergy season. For example, Alcon‘s daily replacement contact lens has an FDA approval for reducing the symptoms of seasonal allergic conjunctivitis related to contact lenses, making them a suitable prescription for patients with ocular allergies. The edge profile on the Dailies Aqua Comfort Plus lens is also very thin, thereby decreasing upper lid interaction and irritation when papillae are present underneath the upper lid.


Bevacizumab, Aflibercept Reduce Macular Edema

Two new studies show that bevacizumab and aflibercept can reduce macular edema and improve visual acuity in patients with central retinal vein occlusion (CRVO). The two drugs block vascular endothelial growth factor (VEGF), as appeared in Ophthalmology.

Visual acuity in the bevacizumab group improved by a mean of 7.5 letters at 6 weeks. 11.4 letters at 12 weeks, 13.9 letters at 18 weeks, and 14.1 letters at 24 weeks. More patients in the bevacizumab group had no residual edema at 24 weeks.

In a second study using aflibercept, at week 24 56.1% of eyes treated had gained 15 letters or more from baseline. Macular edema declined to a significantly greater extent with aflibercept than with a sham treatment.

No serious adverse events with bevacizumab, but there was one case each of endophthalmitis, maculopathy, ocular discomfort, and retinal artery occlusion attributed to aflibercept treatment.